Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients

Shi, Pengfei; Zhou, Min; Yang, Yonggang

doi:10.1007/s11845-019-02071-y

Cited by 12 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SIRT2 has been shown to play a critical role in cancer but it is still inconsistent whether it is an oncogene or a tumor suppressor. In breast cancer, lower SIRT2 expression was detected in cancer tissues as compared with adjacent normal tissues [ 24 , 34 ]. In addition, SIRT2 was also downregulated in metastatic sites as compared with primary sites [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Wang

Kim

et al. 2020

Antioxidants

View full text Add to dashboard Cite

Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer cell death. Sirtuin 2 (SIRT2), a member of class III NAD+ dependent histone deacetylases (HDACs), has been reported to be involved in regulating cancer hallmarks including drug response. In this study, we aimed to identify the role of SIRT2 in oxidative stress and cisplatin response in cancer. Two ovarian cancer cell lines featuring different sensitivities to cisplatin were used in this study. We found different expression patterns of SIRT2 in cisplatin-sensitive (A2780/S) and cisplatin-resistant (A2780/CP) cancer cells with cisplatin treatment, where SIRT2 expression was augmented only in A2780/S cells. Furthermore, cisplatin-induced ROS generation was responsible for the upregulation of SIRT2 in A2780/S cells, whereas overexpression of SIRT2 significantly enhanced the sensitivity of cisplatin-resistant counterpart cells to cisplatin. Our study proposes that targeting SIRT2 may provide new strategies to potentiate platinum-based chemotherapy in ovarian cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Wang

Kim

et al. 2020

Antioxidants

View full text Add to dashboard Cite

show abstract

“…Furthermore, lower SIRT2 expression was observed in metastatic samples suggesting that SIRT2 downregulation may be associated with more aggressive phenotype in breast cancer. This result was supported by Shi et al who demonstrated that high expression of SIRT2 by IHC (IHC score > 3) was lower in tumor tissues compared to the normal adjacent tissues in 296 patients (49). Similarly, McGlynn et al detected that SIRT2 transcripts were significantly lower in malignant breast tissues in comparison to non-malignant or normal breast tissue (50).…”

Section: Sirt2 Expression and The Clinical Outcomementioning

confidence: 79%

The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?

2020

View full text Add to dashboard Cite

Sirtuin 2 (SIRT2) is a member of the sirtuin protein family. It is a Class III histone deacetylase (HDACs) and predominantly localized to the cytosol. SIRT2 deacetylates histones and a number of non-histone proteins and plays a pivotal role in various physiologic processes. Previously, SIRT2 has been considered indispensable during carcinogenesis; however, there is now a significant controversy regarding whether SIRT2 is an oncogene or a tumor suppressor. The purpose of this review is to summarize the physiological functions of SIRT2 and its mechanisms in cancer. We will focus on five malignancies (breast cancer, non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and glioma) to describe the current status of SIRT2 research and discuss the clinical evaluation of SIRT2 expression and the use of SIRT2 inhibitors.

show abstract

“…SIRT2 is an NAD + -dependent deacetylase that plays a crucial role in a variety of processes, such as cell proliferation, in ammation, immunity, and tumorigenesis [6]. It has been reported that increased SIRT2 expression associates with decreased TNM stage and longer survival in patients with breast cancer [23]. Mutation of SIRT2 in human cancers leads to a loss of its deacetylase activity and impaired genomic stability in cancer cells [24].…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer-Secreted Exosomal miR-1275 Modulates Osteoblast Proliferation and Differentiation by Targeting SIRT2/RUNX2 Cascade

Zou¹,

Dai²,

Deng³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCancer-derived exosomes can promote tumor metastasis by delivering miRNAs from cancer cells to recipient cells. miR-1275 is suggested to be an important regulator involved in prostate cancer (PCa) metastasis; however, the association of miR-1275 with the microenvironment of PCa bone metastasis is unclear.Materials and methodsThe level of relative genes and proteins were detected by qPCR and western-blot, cell ability were examined by CCK-8 , the identification of target gene was analyzed by dual-luciferase reporter assay,exosomes were isolated from the PC3-derived conditioned medium by ultracentrifugation.Resultwe found that miR-1275 could be transferred from PCa cells to osteoblasts via exosomes. Exosomal miR-1275 significantly accelerated the proliferation of osteoblasts and the expression levels of osteoblast-specific genes, such as osteocalcin (OCN), type I collagen (COL-1), and osteopontin (OPN). Moreover, exosomal miR-1275 increased the expression of RUNX2, a master modulator of osteoblast differentiation, by down-regulation of SIRT2, which in turn influenced the proliferation and differentiation of osteoblasts.ConclusionsOur findings indicate that exosomal miR-1275 is a promoter of osteoblast activity, which may contribute to PCa bone metastasis.

show abstract

Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients

Cited by 12 publications

References 24 publications

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?

Prostate Cancer-Secreted Exosomal miR-1275 Modulates Osteoblast Proliferation and Differentiation by Targeting SIRT2/RUNX2 Cascade

Contact Info

Product

Resources

About